Free tool
FAERS Monitor: Quzyttir
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211415 or its brand name (Quzyttir, Cetirizine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
31,397
Serious
24,248
77% of reports
Hospitalization
9,666
Death reported
5,131
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9,563
- pain8,983
- fatigue8,946
- alopecia7,541
- rheumatoid arthritis7,475
- abdominal discomfort7,448
- systemic lupus erythematosus7,162
- pemphigus7,032
- off label use6,781
- rash6,691
- glossodynia6,533
- swelling6,091
- hypersensitivity5,812
- hand deformity5,687
- infusion related reaction5,618
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 60 |
| 2006 | 20 |
| 2007 | 66 |
| 2008 | 169 |
| 2009 | 159 |
| 2010 | 137 |
| 2011 | 137 |
| 2012 | 159 |
| 2013 | 208 |
| 2014 | 240 |
| 2015 | 359 |
| 2016 | 814 |
| 2017 | 874 |
| 2018 | 1,009 |
| 2019 | 1,555 |
| 2020 | 2,155 |
| 2021 | 4,402 |
| 2022 | 4,406 |
| 2023 | 3,425 |
| 2024 | 4,299 |
| 2025 | 4,038 |
| 2026 | 2,687 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,762 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 7,032 | 858.9 | 830.6 | 2,640,874 |
| hand deformitySignal | 5,687 | 511.6 | 495.1 | 1,643,608 |
| glossodyniaSignal | 6,533 | 275.6 | 268.3 | 1,267,248 |
| systemic lupus erythematosusSignal | 7,162 | 169.1 | 165.1 | 956,768 |
| infusion related reactionSignal | 5,618 | 61.9 | 60.4 | 309,213 |
| rheumatoid arthritisSignal | 7,475 | 47.1 | 46.2 | 317,060 |
| swellingSignal | 6,091 | 46.6 | 45.5 | 254,990 |
| abdominal discomfortSignal | 7,448 | 31.1 | 30.4 | 208,828 |
| alopeciaSignal | 7,541 | 26.7 | 26.2 | 181,128 |
| hypersensitivitySignal | 5,812 | 21.6 | 21.1 | 111,690 |
| rashSignal | 6,691 | 10.4 | 10.2 | 57,334 |
| painSignal | 8,983 | 9.9 | 9.8 | 73,187 |
| fatigueSignal | 8,946 | 7.8 | 7.6 | 54,210 |
| off label useSignal | 6,781 | 5.2 | 5.1 | 23,951 |
| drug ineffectiveSignal | 9,563 | 4.9 | 4.8 | 31,329 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.